

REMARKS

As stated in the Petition for Revival of an Application Unintentionally Abandoned, in order to facilitate prosecution, Applicants are reviving an application filed by another entity (Nixon & Vanderhye) rather than attempting to have their preferred application (filed by Kilpatrick Stockton) reinstated.

In order to have Applicants preferred claims examined, Applicants have canceled Claims 1-18 of the originally filed application and added new Claims 19-38. New Claims 19-38 are duplicates of the claims as filed in the Kilpatrick Stockton Preliminary Amendment of February 12, 2001 (and paid for by Check No. 1301, copy attached as Appendix A). Support for new Claims 19-38 can be found throughout the specification and claims as filed. New Claims 19-38 have been added for the purpose of more clearly defining a structured embodiment, no subject matter is being disclaimed or abandoned and no new matter has been added by these amendments. New Claims 19-38 remove all multiple dependencies from the claims, and place all claims in condition for examination on their merits. These new Claims 19-38 avoid payment of the surcharge for filing multiple-dependent claims.

Applicants would like to draw the Examiner's attention to the Office Action mailed July 3, 2001. That Office Action does not relate to the claims or US Application No. 09/726,630, directed to nimesulide containing topical pharmaceutical compositions. Instead, the Office Action is for US Application No. 09/726,276 and is directed to treating and preventing a physiological disorder associated with an excess of neuropeptide Y.

Applicants respectfully request that a new first Office Action be issued.

VERSION OF AMENDMENTS WITH MARKINGS SHOWING CHANGES

Added text is marked with underline. Deleted text is marked with [square brackets].

Amendments in the Specification:

In accordance with 37 CFR 1.121(b), the following replacement paragraphs show all the changes made by the foregoing amendment relative to the previous version of the paragraphs.

Page 1, Line 3:

TECHNICAL AREA

Page 1, Line 5:

BACKGROUND OF THE INVENTION

Page 1, Line 24:

SUMMARY OF THE INVENTION

Page 2, before Line 1:

DETAILED DESCRIPTION OF THE INVENTION

Amendments in the Claims:

In accordance with 37 CFR 1.121(c), the following versions of the claims as rewritten by the foregoing amendment show all the changes made relative to the previous versions of the claims.

Claims 1-18 are canceled and new Claims 19-38 are added.

CONCLUSION

Applicants assert that the claims are now in condition for allowance and respectfully request that the application be passed to issuance. If the Examiner believes that any informalities remain in the case which may be corrected by Examiner's amendment, or that there are any other issues which can be resolved by a telephone interview, a telephone call to the undersigned attorney at (404) 745-2413 is respectfully solicited.

Respectfully submitted,

Suzanne Seavello Shope

By: Suzanne Seavello Shope
Registration No. 37,933

KILPATRICK STOCKTON, LLP
1100 Peachtree Street
Suite 2800
Atlanta, Georgia 30309-4530
(404) 815-6500
(404) 541-3389 (Facsimile)
Our File: 47513-0100 (253113)

091762, 630

Amendment & Response to Office Action

Page 8 A1

APPENDIX A

09/762,630 Amendment & Response to Office Action, Page A2

FEB 28 '02 14:45 FR WACHOVIA CORP 404 332 4424 TO 94045414673

P.01/01

DDA:13815124

Page 1 of 1

Check Image Archive

Feb 28 2002

Image View

02:28:29 PM

KILPATRICK STOCKTON LLP

OPERATING ACCOUNT
1100 Peachtree Street
Atlanta, Georgia 30309-4530

DATE
02-12-0

NO. 1301

841
810

WACHOVIA
Wachovia Bank of Georgia, N.A.
Atlanta, GA 30383

• PAY FOUR HUNDRED FIFTY-NINE AND 00/100 Dollars

~~\$*****459.00~~

TO
THE
ORDER
OF

**Commissioner of Patents &
Trademarks**

Cat. small

400858366 2373 2924 01 02-30-01

• 13010061000010:

438 151 2400

400000-59002

E 0 2 2 5 W 9 1 4

To: Karen 4.541.4673
From: Sethe

	View Selection	Posting Date	Amount	Serial No.	Sequence No.	Source	Type	Status	Description
1	1	02/20/2001	\$459.00	1301	0000000000006872889	Check	Debit	Post	CHECK

09/762,630 Amendment Response to Office Action, Page 12

Check Number, Bank ID and Check Date

Check Number: 0301

Bank ID: 2

Monetary Disbursement Attachment

Check Date: 02/12/2001

Additional Check Information

Status: CLEARED

Amount: 459.00

Batch #: 02201ER

Doc/Clear Date: 02/18/2001

Discount: 0.00

Check Type: AUTOMATIC

Vendor ID: 1051

Commissioner of Patents

Address/Unit:

Commissioner of Patents

Check Number	Type	Pay Date	Voucher Am.	Edits	Credit	Balance
381854	IN	02/12/2001	459.00	459.00		0.00

Detail

Balance



RECEIVED

NOV 20 2002

OFFICE OF PETITIONS

#15

U9/762630
JC02 Rec'd PCT/PTO 12 FEB 2001

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
EMBIL ET AL.)
Serial No. CONCURRENTLY HEREWITH) Art Unit: To be Assigned
(National Phase of PCT/IB99/01460))
For: NIMESULIDE CONTAINING TOPICAL) Examiner: To be Assigned
PHARMACEUTICAL COMPOSITIONS)

PRELIMINARY AMENDMENT

Assistant Commissioner for Patents
Washington, DC 20231

Please enter the following amendments in the patent application identified above, before calculating the total amount of filing fee required to enter the national phase for that application.


In the Specification:

Please insert the phrase -- TECHNICAL AREA -- at page 1, line 3.

Please insert the phrase -- BACKGROUND OF THE INVENTION -- at page 1, line 5.

Please insert the phrase -- SUMMARY OF THE INVENTION -- at page 1, line 24.

Please insert the phrase -- DETAILED DESCRIPTION OF THE INVENTION -- at page 2, before line 1.



In the claims

Cancel claims 1-18.

Add new claims 19-38.

We claim:

19. A composition comprising nimesulide and 17% to 59% by weight of a glyceryl monoolein-solvent-phase, wherein the nimesulide is in the glyceryl monoolein-solvent-phase.
20. The composition of claim 19, wherein glyceryl monoolein-solvent phase has a liquid crystal structure.
21. The composition of claim 19, wherein the nimesulide comprises 0.1% to 5% by weight of the composition.
22. The composition of claim 19, further comprising a non-aqueous solvent.
23. The composition of claim 22, wherein the non-aqueous solvent is selected from the group consisting of diethylene glycol monoethyl ether (DGME) and ethanol.
24. The composition of claim 22, further comprising a gelling agent.
25. The composition of claim 24, wherein the gelling agent is hydroxypropylcellulose.
26. A process, comprising:
 - a. dissolving nimesulide in a non-aqueous solvent;
 - b. heating the nimesulide and the non-aqueous solvent of step a to 30° to 90°C;
 - c. heating glyceryl monoolein to 35° to 55°C;

d. mixing the nimesulide and the non-aqueous solvent of step a with the glyceryl monoolein of step c; and,

e. allowing the mixture of step d to cool to room temperature with constant agitation.

27. The process of claim 26, wherein a gelling agent is added at a step selected from the group consisting of step a, step c, step d and step e.

28. A process comprising:

a. dissolving glyceryl monoolein in a non-aqueous solvent;

b. heating the glyceryl monoolein and the non-aqueous solvent of step a to 30° to 90°C;

c. mixing nimesulide into the glyceryl monoolein and the non-aqueous solvent of step b; and,

d. allowing the mixture of step c to cool to room temperature with constant agitation.

29. The process of claim 28, wherein a gelling agent is added at a step selected from the group consisting of step a, step c and step d.

30. A method, wherein a composition comprising nimesulide and 17% to 59% by weight of a glyceryl monoolein-solvent-phase, wherein the nimesulide is in the glyceryl monoolein-solvent phase, is administered to an animal in need of treatment for an indication selected from the group consisting of pain, inflammation and stiffness in amount effective to treat the animal.

31. The method of claim 30, wherein glyceryl monoolein-solvent phase has a liquid crystal structure.

32. The method of claim 30, wherein the nimesulide comprises 0.1% to 5% by weight of the composition.

33. The method of claim 30, further comprising a non-aqueous solvent.
34. The method of claim 33, wherein the non-aqueous solvent is selected from the group consisting of diethylene glycol monoethyl ether (DGME) and ethanol.
35. The method of claim 30, further comprising a gelling agent.
36. The method of claim 35, wherein the gelling agent is hydroxypropylcellulose.
37. The method of claim 30, wherein the composition is administered in a form selected from the group consisting of a gel, a solution, an ointment and a spray.
38. The method of claim 37, wherein the composition is administered in the form of a gel.

REMARKS

To facilitate prosecution, Applicants have canceled claims 1 and 18 and added new claims 19-38. Support for new claims 19-38 can be found throughout the specification and claims as filed. New claims 19-38 have been added for the purpose of more clearly defining a structured embodiment, no subject matter is being disclaimed or abandoned and no new matter has been added by these amendments. New claims 19-38 remove all multiple dependencies from the claims, and place all claims in condition for examination on their merits. These new claims 19-38 avoid payment of the surcharge for filing a multiple-dependent claims.

Applicants respectfully requests entry of this preliminary amendment before examination of the application.

Respectfully submitted,



By: Mary Anthony Merchant, Ph.D.
Registration No. 39,771

KILPATRICK STOCKTON, LLP
2400 Monarch Tower
3424 Peachtree Road, N.E.
Atlanta, GA 30326
(404) 949-3999
(404) 949-3990 (Facsimile)
Our File: 47513-0100 (253113)

33389



The
Patent
Office

PCT/1899/01460



INVESTOR IN PEOPLE

1899/1460 09/762630

**PRIORITY
DOCUMENT**

SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)

REC'D 29 NOV 1999
WIPO PCT

EJU

The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ


I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

I also certify that the attached copy of the request for grant of a Patent (Form 1/77) bears an amendment, effected by this office, following a request by the applicant and agreed to by the Comptroller-General.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.


R. Mahoney
Signed 

Dated 17 August 1999

JC06 Rec'd PCT/PTO 12 FEB 2001

FUMI PTO-1390 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE (Rev. 1-98)		Attorney's Docket Number 47513-253113 (0100)
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371		U.S. Application No. (if known, see 37 CFR 1.5) U91762630
International Application No. PCT/IB99/01460	International Filing Date 12.08.99 (12 August 1999)	Priority Date Claimed 12.08.98 (12 August 1998)
Title of Invention NIMESULIDE CONTAINING TOPICAL PHARMACEUTICAL COMPOSITIONS		
Applicant(s) for DO/EO/US EMBIL, Koral FIGUEROA, Ray		
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:		
<ol style="list-style-type: none">1. <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.2. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.3. <input type="checkbox"/> This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).4. <input checked="" type="checkbox"/> A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2))<ol style="list-style-type: none">a. <input type="checkbox"/> is transmitted herewith (required only if not transmitted by the International Bureau).b. <input checked="" type="checkbox"/> has been transmitted by the International Bureau.c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US).6. <input type="checkbox"/> A translation of the International Application into English (35 U.S.C. 371(c)(2)).7. <input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))<ol style="list-style-type: none">a. <input type="checkbox"/> are transmitted herewith (required only if not transmitted by the International Bureau).b. <input type="checkbox"/> have been transmitted by the International Bureau.c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired.d. <input checked="" type="checkbox"/> have not been made and will not be made.8. <input type="checkbox"/> A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).9. <input checked="" type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).10. <input type="checkbox"/> A translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).		
Items 11. to 16. below concern document(s) or information included:		
<ol style="list-style-type: none">11. <input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98.12. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.13. <input checked="" type="checkbox"/> A FIRST preliminary amendment. <input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment.14. <input type="checkbox"/> A substitute specification.15. <input type="checkbox"/> A change of power of attorney and/or address letter.16. <input type="checkbox"/> Other items or information:		
Express Mail Label No.EL329854525US		Date: February 12, 2001
		Page 1 of 2

JC02 Rec'd PCT/PTO

12 FEB 2001

U.S. 091762630	International Application No. 'CT/IB99/01460	Attorney's Docket Number 47513-253113 (0100)
<u>CALCULATIONS PTO USE ONLY</u>		
17. <input checked="" type="checkbox"/> The following fees are submitted:		
BASIC NATIONAL FEE (37 CFR 1.492(a)(1)-(5)):		
Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO \$970.00		
International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO \$840.00		
International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO..... \$760.00		
International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4) \$670.00		
International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4) \$96.00		
ENTER APPROPRIATE BASIC FEE AMOUNT = \$840		
Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input checked="" type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e)).		
Claims	Number Filed	Number Extra
Total claims	20 - 20 =	0
Independent Claims	4 - 3 =	1
Multiple Dependent Claims (if applicable)		+ 260.00
TOTAL OF ABOVE CALCULATIONS = \$918		
Reduction of 1/2 for filing by small entity, if applicable. Applicant claims small entity status.		
SUBTOTAL = \$918		
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input checked="" type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).		
TOTAL NATIONAL FEE = \$459		
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property		
TOTAL FEES ENCLOSED = \$459		
		Amount to be refunded: \$
		charged: \$
a. <input checked="" type="checkbox"/> A check in the amount of \$459 to cover the above fees is enclosed.		
b. <input type="checkbox"/> Please charge my Deposit Account No. 11-0855 in the amount of \$ _____ to cover the above fees. A duplicate copy of this sheet is enclosed.		
c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Deposit Account No. 11-0855. A duplicate copy of this sheet is enclosed.		
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.		
SEND ALL CORRESPONDENCE TO: Leona G. Young, Ph.D. Kilpatrick Stockton, LLP 2400 Monarch Tower, 3424 Peachtree Road, N.E. Atlanta, Georgia 30326 Telephone: 404-949-2400		
FORM PTO-1390 (Rev. 1-98) adapted		

Mary Anthony Merchant, Reg. No. 39,771

DECLARATION AND POWER OF ATTORNEY

Attorney's Docket No. 47513-0100 (253113)

In re Application of: Koral Embil and Ray Figueroa
As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name. I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled: Nimesulide Containing Topical Pharmaceutical Compositions, the specification of which:

is attached hereto.

was filed on _____ as Application No. _____ (if applicable) and was amended on _____

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above. I do not know and do not believe that the same was ever known or used by others in the United States of America before my or our invention thereof, or patented or described in any printed publication in any country before my or our invention thereof or more than one year prior to the date of this application. I further state that the invention was not in public use or on sale in the United States of America more than one year prior to the date of this application. *I understand that I have a duty of candor and good faith toward the Patent and Trademark Office, and I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, §1.56.*

I hereby claim foreign priority benefits under Title 35, United States Code, §119 (a)-(d) of the foreign application(s) for patent or Inventor's certificate listed below, and have also identified below any foreign application for patent or Inventor's certificate disclosing subject matter in common with the above-identified specification and having a filing date before that of the application on which priority is claimed:

Application No.	Country	Filing Date	Priority Claimed Under 35 USC §119
9817573.0	GB	12 August 1998	Yes <input checked="" type="checkbox"/> No _____

I hereby claim the benefit under Title 35, United States Code, § 119(e) of any United States provisional application(s) listed below:

(Application No.)	(Filing Date)	(Application No.)	(Filing Date)
-------------------	---------------	-------------------	---------------

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed below and, insofar as the subject matter disclosed and claimed in the present application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code §112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, §1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application:

Application Serial No.	Filing Date	Status: patented, pending, abandoned
------------------------	-------------	--------------------------------------

I further declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patents issuing thereon.

POWER OF ATTORNEY: The following attorneys are hereby appointed to prosecute this application and transact all business in the Patent and Trademark Office connected therewith: Customer Number 23594

Direct all correspondence to: Customer Number 23594

Direct telephone calls at 404-949-3999, to Leona G. Young, Ph.D.

AFFIX BAR
CODE LABEL →
HERE



Full name of sole or first inventor: Koral Embil	Citizenship: T.C.
Inventor's signature:	Date: FEBRUARY 12, 2001
Residence and Post Office Address: Mihalane Sokak No: 40, Bomonti, Sisli 80630, Istanbul, Turkey	

Additional inventors are being named on separately numbered sheets attached hereto.

Attorney Docket No.: 47513-0100 (253113)
Title: Nimesulide Containing Topical Pharmaceutical Compositions
Page 2

Full name of second inventor, if any:	Ray Figueroa	Citizenship:	United States of America
Inventor's signature	<i>Ray Figueroa</i>	Date:	2-9-01
Residence and Post Office Address: 8424 N.W. South River Drive, Medley, Florida 33166			

32257

FEB. 28. 2002 3:41PM KILPATRICK STOCKTON

NO. 1355 D. 5/15

KILPATRICK STOCKTON LLP
OPERATING ACCOUNT
1100 Peachtree Street
Atlanta, Georgia 30309-1630

DATE
02-28-01

NO. 1301

WACHOVIA
Wachovia Bank of Georgia, N.A.
Atlanta, GA 30383

FOUR HUNDRED FIFTY-NINE AND 00/100 Dollars

Commissioner of Patents &
Trademarks

\$.....459.00

VOID AFTER 120 DAYS
TWO SIGNATURES REQUIRED OVER SIGN

John S. McAllister

1301-00610000101 13815124

FORM PTO-1390 (REV 11-2000)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTORNEY'S DOCKET NUMBER 888-50
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371		U.S. APPLICATION NO. (If known, see 37 C.F.R. 1.5) 09/762,630
INTERNATIONAL APPLICATION NO. PCT/IB99/01460	INTERNATIONAL FILING DATE 12 August 1999	PRIORITY DATE CLAIMED 12 August 1998
TITLE OF INVENTION NIMESULIDE CONTAINING TOPICAL PHARMACEUTICAL COMPOSITIONS		
APPLICANT(S) FOR DO/EO/US EMBIL, et al.		
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:		
<ol style="list-style-type: none"> 1. <input type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371. 2. <input checked="" type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371. 3. <input type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below. 4. <input type="checkbox"/> The U.S. has been elected by the expiration of 19 months from the priority date (Article 31). 5. A copy of the International Application as filed (35 U.S.C. 371(c)(2)). <ol style="list-style-type: none"> a. <input type="checkbox"/> is attached hereto (required only if not communicated by the International Bureau). b. <input type="checkbox"/> has been communicated by the International Bureau. c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US). 6. <input type="checkbox"/> An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)). <ol style="list-style-type: none"> a. <input type="checkbox"/> is attached hereto. b. <input type="checkbox"/> has been previously submitted under 35 U.S.C. 154(d)(4). 7. <input type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) <ol style="list-style-type: none"> a. <input type="checkbox"/> are attached hereto (required only if not communicated by the International Bureau). b. <input type="checkbox"/> have been communicated by the International Bureau. c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired. d. <input type="checkbox"/> have not been made and will not be made. 8. <input type="checkbox"/> An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). 9. <input checked="" type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). 10. <input type="checkbox"/> An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)). 		
Items 11 To 20 below concern document(s) or information included:		
<ol style="list-style-type: none"> 11. <input type="checkbox"/> An Information Disclosure Statement under 37 C.F.R. 1.97 and 1.98. 12. <input checked="" type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 C.F.R. 3.28 and 3.31 is included. 13. <input type="checkbox"/> A FIRST preliminary amendment. 14. <input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment. 15. <input type="checkbox"/> A substitute specification. 16. <input type="checkbox"/> A change of power of attorney and/or address letter. 17. <input type="checkbox"/> A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821-1.825. 18. <input type="checkbox"/> A second copy of the published international application under 35 U.S.C. 154(d)(4). 19. <input type="checkbox"/> A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4). 20. <input type="checkbox"/> Other items or information. 		

EXHIBIT

tables*

B

U.S. APPLICATION NO. (If known, see 37 C.F.R. 1.5) 09/762,630	INTERNATIONAL APPLICATION NO. PCT/IB99/01460	ATTORNEY'S DOCKET NUMBER 888-50																					
21. <input checked="" type="checkbox"/> The following fees are submitted: BASIC NATIONAL FEE (37 C.F.R. 1.492(a)(1)-(5):		CALCULATIONS PTO USE ONLY																					
<ul style="list-style-type: none"> -- Neither international preliminary examination fee (37 C.F.R. 1.482) nor international search fee (37 C.F.R. 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO \$1000.00 -- International preliminary examination fee (37 C.F.R. 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO \$860.00 -- International preliminary examination fee (37 C.F.R. 1.482) not paid to USPTO but international search fee (37 C.F.R. 1.445(a)(2)) paid to USPTO \$710.00 -- International preliminary examination fee (37 C.F.R. 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4) \$690.00 -- International preliminary examination fee (37 C.F.R. 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4) \$100.00 																							
ENTER APPROPRIATE BASIC FEE AMOUNT =		\$ 0.00																					
Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input checked="" type="checkbox"/> 30 months from the earliest claimed priority date (37 C.F.R. 1.492(e)).		\$ 0.00																					
<table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th>CLAIMS</th> <th>NUMBER FILED</th> <th>NUMBER EXTRA</th> <th>RATE</th> </tr> </thead> <tbody> <tr> <td>Total Claims</td> <td>20</td> <td>-20 =</td> <td>\$ 18.00</td> </tr> <tr> <td>Independent Claims</td> <td>3</td> <td>-3 =</td> <td>\$ 80.00</td> </tr> <tr> <td colspan="2">MULTIPLE DEPENDENT CLAIMS(S) (if applicable)</td> <td></td> <td>\$270.00</td> </tr> <tr> <td colspan="2"></td> <td></td> <td style="text-align: right;">TOTAL OF ABOVE CALCULATIONS =</td> <td style="text-align: right;">\$ 0.00</td> </tr> </tbody> </table>		CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	Total Claims	20	-20 =	\$ 18.00	Independent Claims	3	-3 =	\$ 80.00	MULTIPLE DEPENDENT CLAIMS(S) (if applicable)			\$270.00				TOTAL OF ABOVE CALCULATIONS =	\$ 0.00	
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE																				
Total Claims	20	-20 =	\$ 18.00																				
Independent Claims	3	-3 =	\$ 80.00																				
MULTIPLE DEPENDENT CLAIMS(S) (if applicable)			\$270.00																				
			TOTAL OF ABOVE CALCULATIONS =	\$ 0.00																			
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.		0.00																					
Processing fee of \$130.00, for furnishing the English Translation later than <input type="checkbox"/> 20 <input checked="" type="checkbox"/> 30 months from the earliest claimed priority date (37 C.F.R. 1.492(f)).		\$ 0.00																					
Fee for recording the enclosed assignment (37 C.F.R. 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 C.F.R. 3.28, 3.31). \$40.00 per property		\$ 40.00																					
<input type="checkbox"/> Petition for one month extension of time		\$ 110.00																					
		TOTAL FEES ENCLOSED =	\$ 150.00																				
		Amount to be: refunded \$ Charged \$																					
a. <input checked="" type="checkbox"/> A check in the amount of \$150.00 to cover the above fees is enclosed. b. <input type="checkbox"/> Please charge my Deposit Account No. 14-1140 in the amount of \$_____ to cover the above fees. A duplicate copy of this form is enclosed. c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 14-1140. A duplicate copy of this form is enclosed. d. <input checked="" type="checkbox"/> The entire content of the foreign application(s), referred to in this application is/are hereby incorporated by reference in this application.																							
NOTE: Where an appropriate time limit under 37 C.F.R. 1.494 or 1.495 has not been met, a petition to revive (37 C.F.R. 1.137(a) or (b)) must be filed and granted to restore the application to pending status.																							
SEND ALL CORRESPONDENCE TO: NIXON & VANDERHYE P.C. 1100 North Glebe Road, 8 th Floor Arlington, Virginia 22201-4714 Telephone: (703) 816-4000																							
		SIGNATURE																					
		<u>Arthur R. Crawford</u>																					
		NAME																					
		25,327																					
		April 10, 2001																					
		REGISTRATION NUMBER																					
		Date																					

888-50
10241.3

Nixon & Vanderhye P.C. (1u/99)
(Domestic Non-Assigned/Foreign) Page 1

RULE 63 (37 C.F.R. 1.63)

**INVENTORS DECLARATION FOR PATENT APPLICATION
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

As a below named inventor, I hereby declare that my residence, mailing address and citizenship are as stated below next to my name, and I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

NIMESULIDE CONTAINING TOPICAL PHARMACEUTICAL COMPOSITIONS

the specification of which (check applicable box(s)):

is attached hereto
 was filed on February 12, 2001 as U.S. Application Serial No. 09/762,630 (Atty Dkt. No. 888-50)
 was filed as PCT International application No. PCT/IB99/01460 on 12 August 1999
and (if applicable to U.S. or PCT application) was amended on

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above. I acknowledge the duty to disclose to the Patent Office all information known to me to be material to patentability as defined in 37 C.F.R. 1.56. I hereby claim foreign priority benefits under 35 U.S.C. 119/365 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed or, if no priority is claimed, before the filing date of this application:

Priority Foreign Application(s):

Application Number	Country	Day/Month/Year Filed
--------------------	---------	----------------------

I hereby claim the benefit under 35 U.S.C. §119(e) of any United States provisional application(s) listed below.

Application Number	Date/Month/Year Filed
--------------------	-----------------------

I hereby claim the benefit under 35 U.S.C. 120/365 of all prior United States and PCT international applications listed above or below:

Prior U.S./PCT Application(s):	Day/Month/Year Filed	Status: patented pending, abandoned
Application Serial No. <u>PCT/IB99/01460</u>	<u>12 August 1999</u>	

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon. And on behalf of the owner(s) hereof, I hereby appoint **NIXON & VANDERHYE P.C., 1100 North Glebe Rd., 9th Floor, Arlington, VA 22201-4714**, telephone number **(703) 816-4000** (to whom all communications are to be directed), and the following attorneys thereof (of the same address) individually and collectively owner's/owners' attorneys to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith and with the resulting patent: Larry S. Nixon, 25640; Arthur R. Crawford, 25327; James T. Hosmer, 30184; Robert W. Faris, 31352; Richard G. Basha, 22770; Mark E. Nusbaum, 32348; Michael J. Keenan, 32106; Bryan H. Davidson, 30251; Stanley C. Spooner, 27393; Leonard C. Mitchard, 29009; Duane M. Byers, 33363; Jeffry H. Nelson, 30481; John R. Lastova, 33149; H. Warren Buman, Jr., 29366; Mary J. Wilson, 32955; J. Scott Davidson, 33489; Alan M. Kagen, 36178; Robert A. Molan, 29834; B. J. Sadoff, 36663; James D. Bergquist, 34776; Updeep S. Gill, 37334; Michael J. Shea, 34725; Donald L. Jackson, 41090; Michelle N. Lester, 32331; Frank P. Presta, 19828; Joseph S. Presta, 35329; Joseph A. Rhoa, 37515; Raymond Y. Mah, 41426; Chris Comuzis, 31097. I also authorize Nixon & Vanderhye to delete any attorney names/numbers no longer with the firm and to act and rely solely on instructions directly communicated from the person, assignee, attorney, firm, or other organization sending instructions to Nixon & Vanderhye on behalf of the owner(s).

1-00	Inventor's Signature: <i>Ray Ray</i>	Date: _____		
	Inventor: _____	Turkey (citizenship) _____		
	Residence: (city) _____	Koral (first) _____	EMBIL (last) _____	
	Mailing Address: _____	MI _____	Turkey (state/country) _____	
	(Zip Code) _____	c/o Embil Pharmaceutical Company Limited, P. O. Box 226, Sisli, Istanbul, Turkey		
2-00	Inventor's Signature: <i>Ray Ray</i>	Date: <u>3/26/01</u>		
	Inventor: _____	United States (citizenship) _____		
	Residence: (city) _____	Ray (first) _____	FIGUEROA (last) _____	
	Mailing Address: _____	MI _____	Florida (state/country) _____	
	(Zip Code) _____	c/o R.F. Technology Consultants, Inc. 8242 N.W. South River Drive, Medley, Florida		

See attached sheet(s) for additional inventor(s) information!!



RECEIVED

JUN 19 2001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE, TECH CENTER 1600/2900

In re Application of:)
Embil et al.)
Serial No. 09/762,630)
Filed: February 12, 2001)
For: Nimesulide Containing Topical)
Pharmaceutical Compositions)

#6
JL
JL
6/29/01

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, DC 20231

Sir:

The citation of information on the attached Form PTO/SB/08 is made pursuant to 37 C.F.R. §§ 1.56, 1.97, and 1.98. A copy of each cited item is enclosed.

The citation of this information does not constitute an admission of priority or that any cited item is available as a reference, or a waiver of any right the applicant may have under applicable statutes, Rules of Practice in patent cases, or otherwise.

Respectfully submitted,

Suzanne Seavello Shope


Suzanne Seavello Shope
Reg. No. 37,933

KILPATRICK STOCKTON LLP
2400 Monarch Tower
3424 Peachtree Road, N.E.
Atlanta, Georgia 30326
(404) 949-3999
Our Docket: 47513-0100 (47513-253113)

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, DC 20231, on June 13, 2001.

Suzanne Seavello Shope
Suzanne Seavello Shope - Reg. No. 37,933

ATLLIB02 47294.1



RECEIVED

NOV 20 2002

OFFICE OF PETITIONS



RECEIVED

NOV 2 02002

OFFICE OF PETITIONS

PTO/SB/08A (08-00)

Approved for use through 10/11/2002 QMB 1651-0004

Approved for use through 10/11/2002 GMB 1651-0864
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

of information unless it contains
Complete if Known

JUN 19 2001

Substitute for Form 1449/A/PTO

JUN 15 200

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 1

Complete if Known	
Application Number	09/762,630
Filing Date	February 13, 2001
First Named Inventor	Koral Embri
Group Art Unit	16002
Examiner Name	
Attorney Docket Number	47513-0100 (47513-253113)

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

Examiner Signature  Date 6/22/2014



RECEIVED

NOV 20 2002

OFFICE OF PETITIONS

Interview Summary	Application No.	Applicant(s)
	09/762,630	EMBIL ET AL.
	Examiner Dwayne C Jones	Art Unit 1614

All participants (applicant, applicant's representative, PTO personnel):

(1) Dwayne C Jones (3) _____

(2) Mr. James T. Hosmer (4) _____

Date of Interview: 26 February 2002.

Type: a) Telephonic b) Video Conference
c) Personal [copy given to: 1) applicant 2) applicant's representative]

Exhibit shown or demonstration conducted: d) Yes e) No.
If Yes, brief description: _____.

Claim(s) discussed: All pending.

Identification of prior art discussed: N/A.

Agreement with respect to the claims f) was reached. g) was not reached. h) N/A.

Substance of Interview including description of the general nature of what was agreed to if an agreement was reached, or any other comments: confirmed the abandoned status of this application.

(A fuller description, if necessary, and a copy of the amendments which the examiner agreed would render the claims allowable, if available, must be attached. Also, where no copy of the amendments that would render the claims allowable is available, a summary thereof must be attached.)


i) It is not necessary for applicant to provide a separate record of the substance of the interview(if box is checked).

Unless the paragraph above has been checked, THE FORMAL WRITTEN REPLY TO THE LAST OFFICE ACTION MUST INCLUDE THE SUBSTANCE OF THE INTERVIEW. (See MPEP Section 713.04). If a reply to the last Office action has already been filed, APPLICANT IS GIVEN ONE MONTH FROM THIS INTERVIEW DATE TO FILE A STATEMENT OF THE SUBSTANCE OF THE INTERVIEW. See Summary of Record of Interview requirements on reverse side or on attached sheet.

Examiner Note: You must sign this form unless it is an Attachment to a signed Office action.

Dwayne C. Jones
PTO
11/14

Examiner's signature, if required



#10



UNITED STATES PATENT AND TRADEMARK OFFICE

 Commissioner for Patents, Box PCT
 United States Patent and Trademark Office
 Washington, D.C. 20231
www.uspto.gov

U.S. APPLICATION NUMBER NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
09/762,630	Koral Embil	888-50
INTERNATIONAL APPLICATION NO.		PCT/IB99/01460
I.A. FILING DATE		PRIORITY DATE
08/12/1999		
CONFIRMATION NO. 6577		
 *OC000000007719975*		

Date Mailed: 03/26/2002

NOTICE OF CANCELLATION OF ASSIGNED SERIAL NUMBER

Documents filed under 35 U.S.C. 371 to enter the national stage before the US Designated/Elected Office were received by the US Patent and Trademark Office on 2/12/01 and assigned serial number 9/762630.

Documents filed later under 35 U.S.C. 371 and 37 CFR 1.494 or 1.495 were received on 2/12/01 and assigned serial number 9/762776.

The assigned serial number 9/762776 has been cancelled and other assigned serial number should be used when filing papers in the Patent and Trademark Office.

Note: 09/762630 - Currently abandoned

Applicant will be receiving further communications concerning 35 U.S.C. 371 in due course.

Applicant is reminded that any communication mailed to the United States Patent and Trademark Office must be directed to the address and include the U.S. application no. in the heading above (37 CFR 1.5).

DONNA S GREENE

Telephone: (703) 305-3619


PART 3 - OFFICE COPY

FORM PCT/DO/EO/908 (Canceled Application Number)

RECEIVED

NOV 20 2002

OFFICE OF PETITIONS



JC06 Rec'd PCT/PTO 12 FEB 2001

The U.S. Patent & Trademark Office official Mailroom stamp affixed hereto, acknowledges receipt of the items checked below:

Application No.: Filed Concurrently Filing Date: February 12, 2001

Inventor: Koral Embil and Ray Figueroa

Title: NIMESULIDE CONTAINING TOPICAL PHARMACEUTICAL COMPOSITIONS


Enclosures: Transmittal Letter to the United States Designated/Elected Office (DO/EO/US) Concerning a Filing Under 35 U.S.C. 371, 2 pages; Preliminary Amendment; Declaration and Power of Attorney, 2 pages; check - \$459.00

Docket No.: 47513-0100 (253113)
Atty/Sec'y: LGY/BB/lcb
Date Mailed: February 12, 2001


09/762630

SEARCHED
4/4

4/4



SM 4/4/02 253113




The U.S. Patent & Trademark Office official Mailroom stamp affixed hereto,
acknowledges receipt of the items listed below:

Application No: 09/762,630
Application Date.: February 12, 2001

Inventor: Koral Embil et al.

For: Nimesulide Containing Topical Pharmaceutical Compositions
Papers Submitted: Power of Attorney or Authorization of Agent of
Ramon Figueroa, Revocation of Power of Attorney or
Authorization of Agent of Ramon Figueroa
Power of Attorney or Authorization of Agent of Koral Embil,
Revocation of Power of Attorney or Authorization of Agent of
Koral Embil


Docket No.: 47513-0100 (253113)
Date Mailed June 5, 2002
Atty/Sec'y: JAM:ckf



RECEIVED

NOV 2 0 2002

OFFICE OF PETITIONS



Please type a plus sign (X) inside this box

PTO/SB/82 (10-00)

Approved for use through 10/31/2002. OMB 0651-0035
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**POWER OF ATTORNEY OR
AUTHORIZATION OF AGENT**

Application Number	09/762,630
Filing Date	February 12, 2001
First Named Inventor	Koral Embil
Title	Nimesulide Containing Topical Pharmaceutical Compositions
Group Art Unit	1614
Examiner Name	Dwayne C. Jones
Attorney Docket Number	47513-0100 (47513-253113)

I hereby appoint:

Practitioners at Customer Number.
OR
 Practitioner(s) named below:



Name	Registration Number


as my/our attorney(s) or agent(s) to prosecute the application identified above, and to transact all business in the United States Patent and Trademark Office connected therewith.

Please change the correspondence address for the above-identified application to:

The above-mentioned Customer Number

OR

Practitioners at Customer Number.



Place Customer
Number Bar Code
Label here

OR

Firm or
Individual Name

Address

Address

City

State

ZIP

Country

Telephone

Fax

I am the:

Applicant/Inventor.

Assignee of record of the entire interest. See 37 CFR 3.71.
Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96).

RECEIVED

SIGNATURE of Applicant or Assignee of Record


NOV 20 2002

Name	Ramon-Figueroa	OFFICE OF PETITIONS
Signature		
Date	1/29/02	

NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below*.

*Total of 4 forms are submitted.

Burden Hour Statement: This form is estimated to take 3 minutes to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



KILPATRICK STOCKTON

NO. 3229 P. 3

Please checkmark (X) inside this box



PTO/SB/82 (10-00)

Approved for use through 10-31-2002. OMB 0651-0035

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

POWER OF ATTORNEY OR
AUTHORIZATION OF AGENT

Application Number	09/782,630
Filing Date	February 12, 2001
First Named Inventor	Koral Embil
Title	Nimesulide Containing Topical Pharmaceutical Compositions
Group Art Unit	1814
Examiner Name	Dwayne C. Jones
Attorney Docket Number	47513-0100 (47513-253113)

I hereby appoint:

Practitioners at Customer Number.
OR
 Practitioner(s) named below:



Name	Registration Number

as my/our attorney(s) or agent(s) to prosecute the application identified above, and to transact all business in the United States Patent and Trademark Office connected therewith.

Please change the correspondence address for the above-identified application to:

The above-mentioned Customer Number

OR

Practitioners at Customer Number.

OR

Firm or
Individual Name

Address

Address

City

State

ZIP

Country

Telephone

Fax


Place Customer
Number Bar Code
Label here

I am the:

Applicant/Inventor.

Assignee of record of the entire interest. See 37 CFR 3.71.
Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96).

SIGNATURE of Applicant or Assignee of Record

Name	Koral Embil
Signature	
Date	May 9, 2002

NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below.

Total of 4 forms are submitted.

Burden Hour Statement: This form is estimated to take 3 minutes to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.


ATL1003 62492.1

RECEIVED

NOV 2 0 2002

OFFICE OF PETITIONS

Please type a plus sign (+) inside this box



PTO/SB/82 (10-00)

Approved for use through 10/31/2002. GMB 0691-0035

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

REVOCATION OF POWER OF ATTORNEY OR AUTHORIZATION OF AGENT

Application Number	09/782,830
Filing Date	February 12, 2001
First Named Inventor	Koral Embil
Group Art Unit	1614
Examiner Name	Dwayne C. Jones
Attorney Docket Number	47513-0100 (47513-253113)

I hereby revoke all previous powers of attorney or authorizations of agent given in the above-identified application:

A Power of Attorney or Authorization of Agent is submitted herewith.

OR

Please change the correspondence address for the above-identified application to:

Customer Number



Place Customer
Number Bar Code
Label here

OR

Firm or
Individual Name

Address

Address

City

State

ZIP

Country

Telephone

Fax


I am the:

Applicant/Inventor.

Assignee of record of the entire interest. See 37 CFR 3.71.
Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96)

SIGNATURE of Applicant or Assignee of Record

Name Koral Embil

Signature 


Date May 9, 2002

NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below*.

*Total of 2 forms are submitted.

Burden Hour Statement: This form is estimated to take 3 minutes to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (X) inside this box



PTO/SB/82 (10-00)

Approved for use through 10/31/2002. OMB 0651-0035

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**REVOCATION OF POWER OF
ATTORNEY OR
AUTHORIZATION OF AGENT**

Application Number	09/762,630
Filing Date	February 12, 2001
First Named Inventor	Koral Embil
Group Art Unit	1614
Examiner Name	Dwayne C. Jones
Attorney Docket Number	47513-0100 (47513-253113)

I hereby revoke all previous powers of attorney or authorizations of agent given in the above-identified application:

A Power of Attorney or Authorization of Agent is submitted herewith.

OR

Please change the correspondence address for the above-identified application to:

Customer Number



Place Customer
Number Bar Code
Label here

OR

Firm or
Individual Name

Address

Address

City

State

ZIP

Country

Telephone

Fax

I am the:

Applicant/Inventor.

Assignee of record of the entire interest. See 37 CFR 3.71.
Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96)

SIGNATURE of Applicant or Assignee of Record

Name	Ramon Figueroa
Signature	
Date	5/29/02

NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below*.

*Total of 4 forms are submitted.

Burden Hour Statement: This form is estimated to take 3 minutes to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

RECEIVED

NOV 2 0 2002

OFFICE OF PETITIONS